Aphria Inc (TSX:APHA) Investors: Pay Attention to These 3 Things

Aphria Inc (TSX:APHA)(NYSE:APHA) has a terrible third quarter. Not only is the company struggling to boost production, but costs are also on the rise. As we head into the fourth quarter, be sure to monitor these three trends.

Aphria Inc (TSX:APHA)(NYSE:APHA) stock is under fire. After reporting third quarter earnings, shares fell by 20%.

Based on nearly any metric, the quarter was horrendous. Aphria struggled to bring new production online, experienced rising corporate and packaging costs, and took a $50 million write-down on its newly acquired Latin America assets.

As we head into the fourth quarter, here are three important trends to monitor.

Production guidance

Demand for cannabis worldwide continues to explode. By 2030, Canadian demand could reach $10 billion annually while the U.S. could surpass $40 billion. To meet this heavy growth, cannabis growers are scrambling to ramp production quickly.

Aphria’s management team has revealed its plans to eventually reach $1 billion in annual sales, but recent quarters have thrown that lofty goal into doubt. In fact, the company now anticipates flat revenue growth for the fourth quarter. What happened?

It turns out that scaling commercial-grade facilities in under 12 months is extraordinarily difficult. We’ve seen other disrupters like Elon Musk attempt similar feats and fail.

If Aphria can’t ramp its production this year, it will be leaving millions of dollars on the table. While new production facilities won’t come online until the second half of 2019, pay close attention to the details when management updates its anticipated production growth.

Cost controls

While scaling production can be difficult, doing it in a cost-efficient manner is even more troublesome.

Last quarter, Aphria’s corporate costs went up across the board. Not only did it need to expand its employee count, but Aphria also failed to automate most of its production as promised.

Incredibly, most of its packaging is still done by hand. If it can’t figure out how to automate this core process, Aphria will struggle to bring down costs alongside its competitors.

In April, company executives specifically highlighted their new focus on “automation and the development of new growing facilities,” but declined to give an exact date by which investors should expect these upgrades, instead noting that they are “mid-term” priorities.

Aphria’s management team keeps pushing its cost-cutting efforts into the future, but if it wants to win back the trust of investors, it needs to provide a solid plan for boosting margins.

Short sellers

Short sellers, investors who bet that a stock will fall in value, can wreak havoc in an instant. While many investors choose to ignore short sellers, pegging them as opportunists, it’s critical that you hear and judge their arguments for yourself.

Earlier this year, Quintessential Capital released a report evaluating Aphria’s stock following months of research, including visits to the company’s facilities in Jamaica, Argentina, and Colombia. The conclusion was dire.

Quintessential Capital charged Aphria insiders with creating and buying shell companies, changing their names and then selling them to Aphria at artificially-inflated prices.

The fact that Aphria has already taken a multi-million dollar write-down on its Latin America acquisition adds considerable credence to these allegations.

If Quintessential Capital is correct, there could be at least $200 million in additional write-offs to come.

You can bet that Quintessential Capital will be looking to push more damning information about Aphria public over the next few months. You’ll want to pay attention to anything else they reveal.

Fool contributor Ryan Vanzo has no position in any stocks mentioned.

More on Cannabis Stocks

Farmer smiles near cannabis crop
Cannabis Stocks

TFSA Investors: An Undervalued Cannabis Stock You Can Buy for $500 Right Now

Down almost 70% from all-time highs, Curaleaf is a TSX cannabis stock that trades at an attractive valuation in December…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2026, as Donald Trump Might Ease Cannabis Restrictions?

Down over 99% from all-time highs, Canopy Growth stock might recover in 2026 if the Trump administration reclassifies cannabis products.

Read more »

Researcher works in hemp field
Cannabis Stocks

Forget Tilray and Buy This Cannabis Stock if the U.S. Reclassifies Marijuana in 2026

While Tilray stock gained over 40% on Friday, this cannabis company is a better buy if the U.S. reclassifies marijuana…

Read more »

A cannabis plant grows.
Cannabis Stocks

Aurora Cannabis Surged 21% on Possible Cannabis Reclassification in the U.S. Is ACB Stock Finally a Good Buy?

Down almost 99% from all-time highs, Aurora Cannabis is a beaten-down marijuana stock that offers upside potential in December 2025.

Read more »

four people hold happy emoji masks
Dividend Stocks

Wary of Mining Companies? A Lower-Risk Way to Get in on the Gold and Silver Surge

Frenco-Nevada (TSX:FNV) stock might be a wiser way to play the run in gold prices this year.

Read more »

Cannabis smoke
Cannabis Stocks

Have Cannabis Stocks Totally Gone Up in Smoke?

Let's dive into whether Canadian cannabis stocks are still investable, and what investors should make of the recent volatility in…

Read more »

Researcher works in hemp field
Cannabis Stocks

1 Undervalued Cannabis Stock to Buy and Hold Over the Next Decade

Green Thumb is a beaten-down cannabis stock that trades at a compelling valuation in September 2025.

Read more »

Researcher works in hemp field
Cannabis Stocks

Pot Stocks Rallied Hard in August: Is There More to Come?

Tilray Brands (TSX:TLRY) and the broad basket of pot stocks could heat up from here.

Read more »